Blueprint Medicines reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Blueprint Medicines using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $-0.79 | $-0.71 | -11.3 % |
Q3 | 2024-10-30 | $-0.89 | $-0.96 | 7.29 % |
Q2 | 2024-08-01 | $-0.80 | $-1.29 | 38.0 % |
Q1 | 2024-05-02 | $-1.32 | $-1.66 | 20.5 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $146.37M | $145.18M | 0.82 % |
Q3 | 2024-10-30 | $128.18M | $127.03M | 0.91 % |
Q2 | 2024-08-01 | $138.16M | $103.00M | 34.1 % |
Q1 | 2024-05-02 | $96.12M | $80.43M | 19.5 % |
Blueprint Medicines (BPMC) is scheduled to report earnings on May 1, 2025. The last reported earnings were for reported on February 13, 2025 for Q4.
The Actual EPS was $-0.79, which missed the estimate of $-0.71.
The Actual Revenue was $146.4M, which beat the estimate of $145.2M.
Browse earnings estimates, EPS, and revenue on all stocks.